Timing of MS drug may change disease course

NCT ID NCT05809986

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at Portuguese adults with relapsing multiple sclerosis who are taking ofatumumab (Kesimpta). It compares those who started the drug within three years of diagnosis to those who started later. The goal is to see if earlier treatment leads to less disease activity, such as fewer relapses or brain lesions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofatumumab (Kesimpta)
What this could lead to: If early treatment proves more effective, it may support starting ofatumumab soon after diagnosis to better control multiple sclerosis.
What could go wrong: This is an observational study, not a controlled trial, so results may show correlation, not causation. Individual responses vary, and long-term risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Amadora, 2720-276, Portugal
Novartis Investigative Site
RECRUITING

Guimarães, 4835-044, Portugal
Novartis Investigative Site
RECRUITING

Leiria, 2410-197, Portugal
Novartis Investigative Site
RECRUITING

Lisbon, 1169-050, Portugal
Novartis Investigative Site
RECRUITING

Lisbon, 1349-019, Portugal
Novartis Investigative Site
RECRUITING

Lisbon, 1649-035, Portugal
Novartis Investigative Site
RECRUITING

Matosinhos Municipality, 4454-513, Portugal
Novartis Investigative Site
RECRUITING

Ponte de Lima, 4990-041, Portugal
Novartis Investigative Site
RECRUITING

Porto, 4200 319, Portugal
Novartis Investigative Site
RECRUITING

Setúbal, 2910-549, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.